Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (PRWEB) January 23, 2015 Biofertilizers stimulate ... such as nitrogen and phosphorous through the activities in ... biofertilizers is increasing due to the stress on reducing ... fertilizers. , The report defines and segments the bio ...
(Date:1/22/2015)... January 22, 2015 Shimadzu Scientific ... UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning from ... is ideal for applications in a variety of ... , The user-friendly UV-1280 enables intuitive operation, while ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... Calif., Nov. 21 Accuray,Incorporated (Nasdaq: ARAY ), ... that its president and chief executive officer, Euan S.,Thomson, ... Piper,Jaffray,s Health Care Conference at the Pierre Hotel in ... p.m. EST (9:30 a.m. PST)., A live webcast ...
... TRBN ) today announced that Dr. Peter ... is scheduled to present a,corporate update at the ... held at The New York Palace Hotel. Dr. ... 2:30 p.m. Interested parties may,access the live audio ...
... Nov. 21 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... webcast live during the 19th Annual Piper Jaffray,Health ... 2:30 p.m. Eastern,Time. The presentation will be webcast ... accessed under the Investor Relations tab at ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 3Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference 219th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Southampton Centre for Biomedical Research, established by the ... the University of Southampton, have been awarded 17m ... research facilities. The funding, which is ... NHS and university partnerships, has secured the future ...
... Ga. A research team from Rollins College in Florida ... the source of the coral-killing pathogen that causes white pox ... in the Caribbean, elkhorn coral was listed for protection under ... to white pox disease. The team,s findings have just been ...
... fecal material -- in particular, dog fecal material -- may ... Detroit,s wintertime air, says a new University of Colorado Boulder ... four Midwestern cities in the experiment, two cities had significant ... feces being the most likely source. "We found ...
Cached Biology News:Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 2New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 3
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
... Infinite 200 series of microplate readers combines ... detection in an affordable, easy-to-use platform for ... The unique modular design and adaptability of ... a choice of a monochromator (M200) or ...
...
Biology Products: